Evobrutinib - Merck Serono

Drug Profile

Evobrutinib - Merck Serono

Alternative Names: M-2951; MSC 2364447; MSC2364447C

Latest Information Update: 06 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Merck Serono
  • Class Antirheumatics; Piperidines; Pyrimidines; Small molecules
  • Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Multiple sclerosis; Rheumatoid arthritis; Systemic lupus erythematosus
  • Phase I Autoimmune disorders
  • Preclinical Encephalomyelitis

Most Recent Events

  • 14 Nov 2017 EMD Serono and Merck completes a phase II trial in Rheumatoid arthritis in USA, Slovakia, Hungary, the Czech Republic, Germany, and Bulgaria (NCT02784106)
  • 25 Oct 2017 Preclinical trials in Encephalomyelitis in USA (PO)
  • 25 Oct 2017 Pharmacodynamics data from preclinical studies in Encephalomyelitis presented at the 7th Joint Congress of the European Committee for Treatment and Research in Multiple Sclerosis and Americas Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top